positive results likely to push this stock significantly higher ,,results expected within 4 weeks . The drug is already partnered with pharma giant Boehringer Ingelheim . Competitors like Genfit , Intercept and Madrigal all valued north of US$500+ Million while Pharmaxis has a laughable valuation of only US$ 54 Million . Positive readout could push stock closer to $1 .GL
"SunTrust Robinson Humphrey's analyst Edward Nash, who has called NASH "one of the last untapped multibillion-dollar therapeutic areas," forecasts the space to grow to more than $5 billion in the U.S. alone by 2028. Research and consulting firm GlobalData estimates the NASH space across seven major markets -- the U.S., France, Germany, Italy, Spain, the U.K. and Japan -- is set to rise to $25.3 billion by 2026.
As markets for diseases such as diabetes and hepatitis C become crowded, companies are looking to NASH for their next big break."
- Forums
- ASX - By Stock
- NASH Phase 2 results imminent --A $20+ BILLION Market
positive results likely to push this stock significantly higher...
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.4¢ |
Change
0.009(25.7%) |
Mkt cap ! $52.53M |
Open | High | Low | Value | Volume |
3.6¢ | 4.4¢ | 3.6¢ | $183.9K | 4.656M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1159 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 997342 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1159 | 0.041 |
4 | 625000 | 0.040 |
1 | 22550 | 0.039 |
1 | 250000 | 0.038 |
2 | 502702 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 997342 | 3 |
0.045 | 129043 | 2 |
0.046 | 101217 | 2 |
0.048 | 254667 | 1 |
0.049 | 71945 | 5 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |